[go: up one dir, main page]

Krasemann et al., 2012 - Google Patents

Non-human primates in prion research

Krasemann et al., 2012

View PDF
Document ID
5006566763699921625
Author
Krasemann S
Sikorska B
Liberski P
Glatzel M
Publication year
Publication venue
Folia Neuropathologica

External Links

Snippet

Prion diseases or transmissible spongiform encephalopathies are neurodegenerative disorders affecting a broad range of mammals including humans. Initially thought to be of viral origin, it became apparent that prion diseases are unique transmissible entities where a …
Continue reading at www.termedia.pl (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Similar Documents

Publication Publication Date Title
Zerr et al. Creutzfeldt–Jakob disease and other prion diseases
Morales et al. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases
Das et al. Prions: beyond a single protein
Bartz Prion strain diversity
Chesebro Introduction to the transmissible spongiform encephalopathies or prion diseases
Hamaguchi et al. The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain
Head et al. Prion diseases
Lotz et al. The role of amyloidogenic protein oligomerization in neurodegenerative disease
Lloyd et al. Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model
Krasemann et al. Non-human primates in prion research
Whitechurch et al. Prion diseases
Comoy et al. Non-human primates in prion diseases
Kovács et al. Rationale for diagnosing human prion disease
Wisniewski et al. Transmissible spongiform encephalopathies
Acín et al. Classical and atypical scrapie in sheep and goats. Review on the etiology, genetic factors, pathogenesis, diagnosis, and control measures of both diseases. Animals. 2021; 11 (3): 691
Liberski et al. Prion diseases
Janka et al. Prion diseases: Update on mad cow disease, variant creutzfeldt-jakob disease, and the transmissible spongiform encephalopathies
Liberski et al. Prion Diseases
EP1528920B1 (en) Suppression of abnormal proliferation of prion proteins with leucine, isoleucine or valine
Schulz-Schaeffer et al. prion diseases: Conformational changes of a protein create an unconventional infectious agent
Belay et al. Prion diseases
Narayan et al. Bovine Spongiform Encephalitis (BSE)/Mad Cow Disease
Kathiriya et al. Transmissible spongiform encephalopathies: Emerging threats
Goldman Prions: From “Slow Viruses” to “Proteinaceous Infectious Particles”
Zanusso et al. Molecular mechanisms of human prion diseases